VISE

Robotic Surgery Pioneer Virtuoso Surgical Awarded $1.8 Million in SBIR Funding

Retrieved on: 
火曜日, 11月 14, 2023
Technology, Radiology, Health Technology, Oncology, Other Science, Research, Medical Devices, Hospitals, Clinical Trials, Biotechnology, Health, Robotics, Women, Seniors, Managed Care, Men, Nanotechnology, Science, Consumer, Medical Supplies, FDA, Hardware, Surgery, Sale, Otorhinolaryngology, Virtuoso, Cadaver, Gynaecology, Lead (engineering), Entrepreneurship, VISE, Surgeon, Elective surgery, Bladder cancer, SBIR, FACS, ENT, NIH, Neurosurgery, Cancer, BPH, Endoscopy, Small Business Innovation Research, Doctor of Philosophy, Uterine fibroid, Medical device, MD, Engineering

Medical device company Virtuoso Surgical, Inc. has been awarded a $1.8 million Small Business Innovation Research (SBIR) NIH grant to be received over the next two years.

Key Points: 
  • Medical device company Virtuoso Surgical, Inc. has been awarded a $1.8 million Small Business Innovation Research (SBIR) NIH grant to be received over the next two years.
  • Virtuoso’s robotic surgery system enables a new scale of robotic tools and maneuvers in endoscopic surgery that are not possible using today’s instruments.
  • “We are honored to receive this SBIR Phase II grant as we move toward commercialization of our groundbreaking robotic surgical system ,” said S. Duke Herrell, III, MD, FACS , CEO, Co-Founder and Chief Medical Officer of Virtuoso Surgical.
  • They developed the Virtuoso Surgical system with a design team helmed by COO, Co-founder and Lead Engineer Richard Hendrick, PhD.

Docupace Adds Acclaimed Sales Leaders to High-Performing Unit

Retrieved on: 
火曜日, 10月 24, 2023
RIAS, Smith, Fiserv, Growth, VISE, Nitrogen, Merrill (company), Investment, Partnership, Sales, Management

LOS ANGELES, Oct. 24, 2023 /PRNewswire/ -- Docupace, the leader in cloud-based fintech digital operations software for the wealth management industry, today announces the continued expansion of its sales organization with additions to its business development and enterprise solutions teams.

Key Points: 
  • "I am incredibly honored and excited to welcome these accomplished professionals to our high-performing group," said Michael Vossler, chief revenue officer for Docupace.
  • Recent expansion of the Docupace sales organization includes the addition of Michael Kroener and Roger Romero as vice presidents – enterprise solutions.
  • Most recently, he led Partnership and Enterprise Sales for VRGL, a client actuation and proposal management platform for wealth enterprises and RIAs.
  • Romero is also a veteran sales professional known for thriving in fast-paced environments and applying a creative approach to sales.

Virtuoso Surgical Unveils Design of Groundbreaking Robotic Surgery System

Retrieved on: 
火曜日, 5月 9, 2023
Biotechnology, Surgery, Health, Medical Devices, Robotics, Hospitals, Health Technology, Technology, ENT, Financial Industry Regulatory Authority, Surgeon, Ear, Elective surgery, BPH, Cadaver, VISE, Bladder cancer, Endoscopy, Doctor of Philosophy, Gynaecology, Sale, Nose, Traction, Neurosurgery, Physician, Uterine fibroid, FACS, Entrepreneurship, Lead (engineering), FDA, III, Urology, Dentistry, Medical device, Engineering, MD

Nashville-based medical device company Virtuoso Surgical, Inc. has unveiled its revolutionary robotic surgery system .

Key Points: 
  • Nashville-based medical device company Virtuoso Surgical, Inc. has unveiled its revolutionary robotic surgery system .
  • “These are groundbreaking maneuvers in endoscopic/endoluminal surgery that are not possible with today’s instruments.”
    The unveiling of the product marks the end of the design stage for Virtuoso Surgical and progress in the regulatory phase.
  • They developed the Virtuoso Surgical system with a design team helmed by COO and Lead Engineer Richard Hendrick, PhD.
  • “Our team set out to bring the stability and dexterity of robotic surgery to the rigid endoscopy space, and we have achieved that with the Virtuoso Surgical system ,” Richard Hendrick, PhD , said.

EndoTheia Inc. Announces FDA Breakthrough Device Designation for Technology to Improve Endoscopic Surgery

Retrieved on: 
火曜日, 1月 10, 2023
FDA, Health, Surgery, Medical Devices, Cadaver, Otorhinolaryngology, Entrepreneurship, University, Face, ESD, Endoscopy, ENT, Surgeon, FDA, Vanderbilt, Neurology, Biliary disease, National Institute of Ear, Nose and Throat (ENT), Bangladesh, Elective surgery, Patient, Urology, VISE, FACS, DRS, Gastroenterology, III, Doctor of Philosophy, Robotics, Surgery, Medical device, Pharmaceutical industry, MD, Engineering

EndoTheia Inc. , a Nashville-based medical device company, announced today that it has gained priority status from the FDA by receiving a Breakthrough Device designation from the agency for its technology that radically improves minimally invasive flexible endoscopic surgery.

Key Points: 
  • EndoTheia Inc. , a Nashville-based medical device company, announced today that it has gained priority status from the FDA by receiving a Breakthrough Device designation from the agency for its technology that radically improves minimally invasive flexible endoscopic surgery.
  • The designation will streamline the regulatory process, enabling EndoTheia to rapidly bring its innovative solution to doctors and patients.
  • EndoTheia’s Breakthrough Device leverages foundational technology that was originally invented at Vanderbilt and the University of Tennessee.
  • S. Duke Herrell, III, MD, FACS, Co-Founder and Chief Medical Officer of EndoTheia , added, "We are excited that the FDA has recognized the huge potential of EndoTheia’s technology through Breakthrough Device designation .

Virtuoso Surgical Announces First Public Offering of Common Stock to Advance its Revolutionary Robotic System for Endoscopic Surgery

Retrieved on: 
火曜日, 9月 13, 2022
Surgery, Medical Devices, Health, Robotics, Technology, National, VISE, Surgery, Gynaecology, Endoscopy, FDA, Elective surgery, Entrepreneurship, Sale, Company, Bladder cancer, Review, Nose, Chief medical informatics officer, Uterine fibroid, U.S. Securities and Exchange Commission, III, Technology, National Science Foundation, Interim, Financial Industry Regulatory Authority, Virtuoso, Doctor of Philosophy, Johns Hopkins University, Surgeon, Cadaver, ENT, Neurology, Vanderbilt University, Ear, SEC, Thorax, Urology, BPH, FACS, Medical device, Dentistry, Engineering, MD

Virtuoso Surgical has developed a robotic surgery system that radically improves minimally invasive endoscopic surgery.

Key Points: 
  • Virtuoso Surgical has developed a robotic surgery system that radically improves minimally invasive endoscopic surgery.
  • Virtuoso Surgicals offering is made under SEC Regulation A, Tier 2, which means that any U.S. person can invest in the Company .
  • The offering is for the sale of common stock, and this is the first offering of the Company's common stock to the public.
  • S. Duke Herrell, III, MD, FACS , Co-Founder, Interim CEO and Chief Medical Officer of Virtuoso Surgical, added, "We are excited about the opportunity to sell our common stock to the public.